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Aim of the study: The aim of the current study is to assess single nucleotide polymorphism (SNP) in
the promoter region of IL-10, TNF-a, IFN-c and TGF-b as predictors of response to combined
Pegylated interferon a/ribavirin (PEG–IFN/RBV) therapy in chronic HCV infected Egyptian patients.
Patients and methods: The study was conducted on 150 HCV infected patients and 100 apparently
healthy control subjects. All patients were treated with PEG–IFN/RBV. They were classified
according to their response to treatment.
Genotyping of IL-10, TNF-a, IFN-c and TGF-b were performed on peripheral blood DNA using
polymerase chain reaction–restriction fragment-length polymorphism (PCR–RFLP) and primer
specific assays.
Results: Overall, 83/150 (55.3%) patients achieved sustained virological response (SVR), whereas
67 (44.7%) did not. Age and BMI were significantly lower in patients who achieved SVR
(P< 0.05). IL-10 at site (1082) GG genotype was associated with SVR where odds ratio was 1.98
with 95% confidence interval (1.34–3.65). None of the other genes showed a significant association
with SVR.
Conclusion: Analysis of IL-10 SNP at promoter site (1082) could be used as a pretreatment
predictor of response to combined PEG–IFN/RBV treatment.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).infected
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Hepatitis C virus (HCV) infection is an important public
health problem, which affects more than 170 million persons
worldwide [1]. The long-term impact of HCV infection is
highly variable, ranging from minimal histological changes
to extensive fibrosis and cirrhosis or hepatocellular carcinoma
(HCC) [2]. Interferon had been the cornerstone of HCV ther-
apy for almost two decades [3]. Direct-acting anti-viral (DAA)
drugs active against different targets of HCV became avail-
able. These potent anti-HCV drugs may be combined with
Pegylated interferon a/ribavirin (PEG–IFN/RBV) according
to recent guidelines [4,5]. Attempts to identify factors predict-
ing favorable response to therapy showed that sustained
virological response (SVR) rates with PEG–IFN/RBV are
dependent on a multitude of host and viral factors. However,
current data on genotype 4 (G4) chronic hepatitis C (CHC)
regarding treatment responsiveness and duration are limited
and controversial [6].
A strong natural killer (NK) cell and T helper 1 (Th1)
cell-mediated immune response seems to be a key factor in
the protection against HCV infection [7]. In addition, viral per-
sistence and a deficient response to antiviral therapy have been
associated with the production of inappropriate levels of
cytokines [8]. Interleukin 10 (IL-10) is a multifunctional cyto-
kine produced by macrophages, monocytes, and T-helper cells
that down regulates the synthesis of pro-inflammatory cytoki-
nes and has a modulatory effect on hepatic fibrogenesis [9].
Heterogeneity in the promoter region of the IL-10 gene has
been reported to have a role in determining the initial and sus-
tained response of chronic hepatitis C to IFN-a therapy [10].
Tumor necrosis factor alpha (TNF-a) may play a role in the
pathogenesis of acute and chronic HCV infection. Some
genetic polymorphisms in the human TNF-a promoter region,
such as the G-to-A transition at positions +308 have been
shown to influence TNF-a expression [11].
Interferon gamma (IFN-c) is critical for host defense
against a variety of intracellular pathogens, including HCV
[12]. It has been established that the T-to-A polymorphism
at position +874 of the first intron of IFN-c gene could
directly influence IFN-c production [13].
Transforming growth factor-b (TGF-b) also can cause
dysregulation of host immune response in chronic HCV
patients [14].
The aim of the work is to assess single nucleotide polymor-
phism (SNP) in the promoter region of IL-10 at sites (1082
G/A, 819 C/T and 592 C/A), TNF-a (308 G/A), IFN-c
(+874 A/T) and TGF-b (+869 T/C and +915 G/C) as predic-
tors of response to antiviral therapy using PEG–IFN/RBV
therapy in Egyptian patients with CHC.
1.1. Patients and methods
This study included 150 consecutive chronic HCV infected
adult patients who were recruited from the National Liver
Institute (NLI), Menoufia University, Egypt in the period from
September 2010 to June 2011. In addition, 100 apparently
healthy subjects of matched age and gender served as the con-
trol group. All patients received antiviral treatment with follow
up protocol according to the standard clinical practice for
18 months. The study was approved by the Institution’s ethicsPlease cite this article in press as: Obada M et al., Impact of genetic polymorphism
Egyptian patients, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhcommittee, and a written informed consent was taken from all
participants enrolled in the study. The work has been carried
out in accordance with The Code of Ethics of the World
Medical Association (Declaration of Helsinki) for experiments
in humans.
Patients had to meet the following criteria:
(1) Treatment naı¨ve patients. (2) They had positive HCV
RNA, higher than1000 IU/mL. (3) Liver biopsy was done
within 3 months before initiation of therapy. (4) Age is not less
than 18 years. (5) Normal thyroid and kidney functions. (6)
No evidence of decompensated liver disease or hepatocellular
carcinoma. (7) No evidence of other etiology of liver disease.
(8) No significant history of cardiovascular or neuropsychiatric
diseases.
All patients received PEG–IFN a-2a administered subcuta-
neously at a dose of 180 lg per week or PEG–IFN a-2b
administered subcutaneously at a dose of 1.5 lg/kg/week and
twice-daily RBV dosed orally according to body weight
(<75 kg, 1000 mg daily; P75 kg, 1200 mg daily). Patients
who failed to achieve EVR (>2 log10 decrease in HCV
RNA at Week 12) or Non-detectable HCV RNA at Week 24
discontinued all therapy. Those who completed 48 weeks of
therapy were followed up for 24 weeks.
Sustained virological response (SVR) was defined as un-
detectable levels of HCV RNA 24 weeks after the completion
of therapy; relapse was defined as detectable HCV RNA
during follow up in patients who had undetectable HCV
RNA at the end of treatment; non-response was defined as
detectable HCV RNA at the end of treatment.
1.2. Laboratory investigations
Baseline blood samples were obtained before commencing
treatment and were analyzed for blood chemistry, HCV
RNA and hematology, using fully automated auto analyzer
SYNCHRON CX9ALX (Beckman Coulter Inc., CA, USA),
COBAS TaqMan HCV assay (Roche Molecular Diagnos-
tics, CA, USA) with lower limit of quantitation of 15 IU/mL,
and Sysmex K-21 (Sysmex Corporation, Kobe, Japan), respec-
tively. Periodic blood samples were taken from patients only
for determination of transaminases, complete blood count
and HCV RNA on weeks (12, 24, and 48) during treatment
and at 6 months after end of treatment.
The histopathological assessment of necro-inflammatory
grade and fibrosis stage were done using the modified Ishak
scoring system before commencing treatment [15].
1.3. Molecular testing
Genomic DNA was extracted from EDTA-treated peripheral
blood using Gene JET Whole Blood Genomic DNA Purifica-
tion Mini Kit, (Thermo Fisher Scientific, MA, USA) (see
Table 1).
1.4. General protocol for PCR–RFLP genotyping
Reaction master mix for amplification constituted of 50 pmol
of each of forward and reverse primers; 12.5 ll of 2 Dream
Taq Green PCR Master Mix (Thermo Fisher Scientific, MA,
USA) and 100 ng of the genomic DNA and the total volume
of reaction was topped up to 25 ll with DNAse-free water.s of four cytokine genes on treatment induced viral clearance in HCV infected
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Table 1 Primers sequences.
Primers sequence Genotyping method Restriction enzyme
IL-10-1082 Forward: 50-TCTGAAGAAGTCCTGATGTCACTG-30 PCR–RFLP MnlI
Reverse: 50-ACTTTCATCTTACCTATCCCTACTTCC-3́
819 Common primer: 50-AGGATGTGTTCCAGGCTCCT-30 Primer specific -
C primer: 50-CCCTTGTACACGTGATGTAAC-30
T primer: 50-ACCCTTGTACAGGTGATGTAAT-30
592 Forward: 50-CCTAGGTCACAGTGACGTGG-30 PCR–RFLP RsaI
Reverse: 50-GGTGAGCACTACCTGACTAGC-30
TNF-a (308) Forward: 50 AGGCAATAGGTTITGAGGGCCAT-30 PCR–RFLP NcoI
Reverse: 50 TCCTCCCTGCTCCGATTCCG-30
INF-c (+874) Forward: 50-TCAACAAAGCTGATACTCCA-30 Primer specific -
(A) Reverse: 50-TTCTTACAACACAAAATCAAATCA-30
(T) Reverse: 50-TTCTTACAACACAAAATCAAATCT-30
TGF-b (+869) (+915) Forward: 50-GTTATTTCCGTGGATACTGAGAC-30 PCR–RFLP MspA1I BglI
Reverse: 50-GACCTCCTTGGCGTAGTAGTCG-30
Figure 1 Agarose gel electrophoresis of PCR–RFLP for IL-10
(1082 G/A) genotypes analysis. Digested and undigested samples
were electrophoresed against a ready-to-use, Gene RulerTM low
range DNA ladder 25–700 bp (Thermo Fisher Scientific, CA,
USA), landmark bands are 100 bp and 300 bp respectively. PCR
product of 196 bp for the undigested samples in lanes 2, 4, 6 and 8,
genotyping was done using restriction enzyme MnlI. Lanes 1, 3
and 5 show G allele with fragments at 58 and 110 bp (fragment 28
was not visualized), while lane 7 shows A with 58 and 138 bp as
well as G allele at 58 bp and 110 bp.
Genetic Polymorphisms and HCV Clearance 3The PCR was performed on Applied Biosystems VeritiTM
thermocycler (Thermo Fisher Scientific Inc., Life Technolo-
giesTM, CA, USA).
After confirmation of successful PCR amplification using
1.5% agarose gel electrophoresis, 10 ll of the amplification
product was added to a digestion mixture of 3 ll buffer (R)
[10 mM Tris–HCl (pH 8.5), 10 mM MgCl2, 100 mM KCl,
0.1 mg/ml BSA], 10 units of an appropriate restriction enzyme
and the volume was topped up with H2O to 30 ll and
incubated at 37 C overnight. The restriction digests were
electrophoresed on 2% Agarose gels (Axygen, CA, USA) for
3 h at 60 V and photographed using InGenius gel documenta-
tion system (Syngene, Cambridge, UK).
1.4.1. Analysis of SNP in the promoter region of the IL-10 at
sites (1082, 819 and 592)
1.4.1.1. IL-10 (1082 G/A) (rs1800896). Genotyping was
done using polymerase chain reaction–restriction fragment
length polymorphism (PCR–RFLP) assay as previously reported
[16,17]. An amplification product 196 bp was obtained using
standard PCR assay, according to cycling conditions consisted
of an initial denaturation step at 94 C for 2 min, followed by
40 cycles of 94 C for 30 s, 59 C for 55 s and 72 C for 45 s, with
a final extension of 72 C for 5 min. The product was digested
using MnlI (Thermo Fisher Scientific, MA, USA) (see Fig. 1).
1.4.1.2. IL-10 (819 C/T) (rs1800871). Genotyping was
performed using primer specific polymerase chain reaction
assay as previously reported [18,19].
A 233-bp fragment spanning position 819 was amplified
using primers with concentration 35 pmol for each primer.
Reaction mix constituted of 35 pmol of each of forward
and reverse primers; 12.5 ll of 2 Dream Taq Green PCR
Master Mix (Thermo Fisher Scientific, MA, USA) and
100 ng of the genomic DNA and the total volume of reaction
was topped up to 25 ll with DNAse-free water. The PCR was
performed on Applied Biosystems VeritiTM thermocycler
(Thermo Fisher Scientific Inc., Life TechnologiesTM, CA,
USA) according to cycling conditions consisting of an initialPlease cite this article in press as: Obada M et al., Impact of genetic polymorphism
Egyptian patients, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhdenaturation step at 95 C for 3 min, followed by 5 cycles of
94 C for 45 s, 70 C for 45 s and 72 C for 20 s, followed by
25 cycles of 95 C for 25 s, 65 C for 50 s and 72 C for 45 s
followed by 5 cycles of 95 C for 25 s, 55 C for 45 s followed
by a final extension of 72 C for 2 min. The PCR product of
233 bp was visualized on the 2% agarose gel (see Fig. 2).s of four cytokine genes on treatment induced viral clearance in HCV infected
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Figure 3 Agarose gel electrophoresis of PCR–RFLP fragments
for IL10 (592 C/A) genotypes analysis. The C allele was
identified by the presence of 412-bp fragment. The A allele had
an RsaI site yielded a 176 bp and 236-bp fragment only. The
samples were electrophoresed against a ready-to-use, Gene RulerTM
low range DNA ladder 25–700 bp (Thermo Fisher Scientific, CA,
USA), landmark bands are 100 bp and 300 bp respectively.
4 M. Obada et al.1.4.1.3. IL-10 (592 C/A) (rs1800872). Genotyping was done
using polymerase chain reaction–restriction fragment length
polymorphism (PCR–RFLP) assay as previously reported [17].
Amplification of 412-bp fragment spanning position 592
was obtained using standard PCR assay, according to cycling
conditions consisted of an initial denaturation step at 94 C for
2 min, followed by 40 cycles of 94 C for 30 s, 59 C for 55 s
and 72 C for 45 s, with a final extension of 72 C for 5 min.
The product was then digested using RsaI (Thermo Fisher
Scientific, MA, USA) (see Fig. 3).
1.4.2. TNF-a gene polymorphism (308 G/A) (rs1800629)
Genotyping was done using polymerase chain reaction–restric-
tion fragment length polymorphism (PCR–RFLP) assay as
previously reported [19]
An amplification product 107 bp was obtained using
standard PCR assay, according to cycling conditions consisted
of an initial denaturation step at 94 C for 3 min, followed by
40 cycles of 94 C for 30 s, 49 C for 45 s and 72 C for 45 s,
with a final extension of 72 C for 5 min. The product was then
digested using restriction enzyme NcoI (Thermo Fisher
Scientific, MA, USA) (see Fig. 4).
1.4.3. INF-c gene polymorphism (+874 A/T) (rs2430561)
Genotyping was performed using primer specific polymerase
chain reaction assay as previously reported [20] where a
261-bp fragment spanning position +874 was amplified.
Reaction mix constituted of 50 pmol of each of forward
and reverse primers; 12.5 ll of 2 Dream Taq Green PCR
Master Mix (Thermo Fisher Scientific, MA, USA) and
100 ng of the genomic DNA and the total volume of reactionFigure 2 Agarose gel electrophoresis of primer specific PCR for
IL-10 (819 C/T) genotypes analysis. Four samples were
electrophoresed against a ready-to-use, Gene RulerTM low range
DNA ladder 25–700 bp (Thermo Fisher Scientific, CA, USA),
landmark bands are 100 bp and 300 bp respectively. PCR product
of 233 bp for the two specific primers for each sample was run in
two consecutive lanes and genotypes were labeled on the gel.
Figure 4 Agarose gel electrophoresis of PCR–RFLP fragments
for TNF-a (308 G/A) genotypes analysis. NcoI restriction site
generate products of 87 bp and (20 bp not evident in gel)
fragments for G allele. The A allele showed 107 bp fragment
only. (GG: lanes 5, 7, 9, 11, 13 – AA: lanes 2, 4, 6, 8, 10, 12 and
GA: lanes 1, 3, 14) The samples were electrophoresed against a
ready-to-use, Gene RulerTM low range DNA ladder 25–700 bp
(Thermo Fisher Scientific, CA, USA), landmark bands are 100 bp
and 300 bp respectively.
Please cite this article in press as: Obada M et al., Impact of genetic polymorphism
Egyptian patients, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhwas topped up to 25 ll with DNAse-free water. The PCR was
performed on Applied Biosystems VeritiTM thermocycler
(Thermo Fisher Scientific Inc., Life TechnologiesTM, CA,
USA) according to cycling conditions consisting of an initial
denaturation step at 96 C for 2.5 min, then 63 C for 60 ss of four cytokine genes on treatment induced viral clearance in HCV infected
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Figure 6 Agarose gel electrophoresis of PCR–RFLP for TGF-b
(+915 G/C) genotypes analysis. The samples were elec-
trophoresed against 100 bp DNA ladder (Thermo Fisher Scien-
tific, CA, USA). Genotypes were labeled on the gel. The restriction
digests for codon 25 where G allele was recognized by fragments
212, 252 (60 bp band was not evident on gel), while the C allele
showed two bands of 212 and 312 bp.
Genetic Polymorphisms and HCV Clearance 5for 1 cycle, followed by 20 cycles of 96 C for 10 s, 60 C for
60 s for 9 cycles then 20 cycles of 96 C for 10 s, 60 C
for 50 s, 72 C for 30 s for, with a final extension of 72 C
for 5 min. The PCR product of 261 bp was visualized on the
2% agarose gel (see Fig. 5).
1.4.4. TGF-b gene polymorphism (+869 T/C) (rs1982073) and
(+915 G/C) (rs1800471)
Genotyping was done using polymerase chain reaction–
restriction fragment length polymorphism (PCR–RFLP) assay
as previously reported [21,22]
Amplification of a fragment spanning position (+869) was
obtained using standard PCR assay, according to cycling con-
ditions consisted of an initial denaturation step at 95 C for
4 min, followed by 40 cycles of 95 C for 30 s, 58 C for 30 s
and 72 for 30 s, with a final extension of 72 C for 10 min.
The product was digested using MspA1I (Thermo Fisher
Scientific, MA, USA) for codon 10 and BglI for codon 25
(Thermo Fisher Scientific, MA, USA).The restriction digests
for codon 10 (+869): T allele was recognized by fragments
40, 67, 108 and 242 bp, while the C allele showed bands of
12, 40, 67, 108, 230 bp (see Fig. 6).
1.5. Statistical analysis
Data analysis was performed using SPSS software for
Windows (version 16.00, SPSS, Inc., Chicago, IL, USA). The
observed alleles frequencies were compared with expected
values calculated from Hardy–Weinberg equilibrium theory.
The data were expressed as mean ± SD or proportions.
Chi-square test or Fisher’s exact test was used for comparison
of categorical variables. Student’s t-test and ANOVA was used
in the case of continuous data. All the significant variables
from univariate analysis as predictors of SVR undergo
stepwise multivariate logistic regression analysis. P-values less
than 0.05 were considered to be statistically significant.
2. Results
The study included 150 consecutive chronic HCV infected
adult patients (99 males and 51 females) with a mean age ofFigure 5 Agarose gel electrophoresis of primer specific PCR for
IFN-c (+874 A/T) genotypes analysis. The samples were
electrophoresed against 100 bp DNA ladder (Thermo Fisher
Scientific, CA, USA). PCR product of 261 bp for the two specific
primers for each sample was run in two consecutive lanes and
genotypes were labeled on the gel.
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(66 males and 34 females) with mean age 43.2 ± 5.72 years
served as the control group. Overall, 83 (55.3%) patients
achieved SVR. Eighteen (12%) patients were relapsers, while
49 (32.7%) patients were non-responders. Patients who achieved
SVR were younger, had lower BMI, less fibrosis and less likely
to be diabetic (Table 2). There was no significant difference of
various polymorphic genetic patterns in chronic HCV patients
compared to controls (Table 3).
▪ Patients with GG genotype of IL-10 (1082 G/A) were
more likely to have SVR than patients with GA or AA
genotypes (Table 4). Odds ratio (OR) was 1.98 (95%
confidence interval (CI): 1.34–3.65, p value <0.05) for
GG genotype versus other genotypes.
▪ There was no significant difference between various geno-
type patterns of IL-10 (819 C/T) and IL-10 (592 C/A)
and also IFN-c (+874 A/T), TNF-a (308 G/A) and
TGF-b codon 10 (+869 T/C) and TGF-b (+915 G/C) as
regards SVR (Table 3).
▪ Multivariate analysis of the factors which were significant
in the univariate analysis revealed that the presence of
GG genotype of IL10 (1082) and fibrosis stage were
the only significant factors predicting SVR. HR 3.0
(95% CI: 1.78–6.12, p value <0.05) and 1.86 (95% CI:
1.35–3.17, p value <0.05) for IL10 (1082) and fibrosis
stage respectively.
3. Discussion
Chronic hepatitis C has been recognized as a progressive
fibrotic liver disease [23]. However, little is known about the
molecular and cellular mechanisms responsible for the
virological response to PEG–IFN/RBV treatment among
patients infected with HCV genotype 4 [24,25].s of four cytokine genes on treatment induced viral clearance in HCV infected
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Table 2 Baseline demographic, biochemical, histological data of HCV infected patients and response to treatment.
Variables All (n= 150) SVR (n= 83) Non-SVR (n= 67) P-value
Age (years) (mean ± SD) 41.60 ± 9.42 38.38 ± 10.07 44.77 ± 8.24 <0.05*
Gender (n (%))
Male 99 (66%) 55 (66.3%) 44 (65.6%) 0.49
Female 51 (34%) 28 (33.7%) 23 (34.4%)
BMI 26.1 ± 3.1 23.7 ± 2.3 27.4 ± 2.3 <0.05*
ALT (IU/L) mean ± SD 43.86 ± 25.48 43.55 ± 26.04 44.33 ± 24.92 0.87
AST (IU/L) mean ± SD 44.46 ± 22.42 45.44 ± 23.50 43.00 ± 20.88 0.54
Hb (gm/dl) 13.16 ± 1.54 13.06 ± 1.67 13.15 ± 1.30 0.76
Platelets (103/mm3) 220.86 ± 71.34 230.54 ± 75.05 204.32 ± 61.93 0.06
AFP (ng/ml) 11.43 ± 5.80 11.85 ± 5.87 10.80 ± 5.72 0.36
Viral load [n (%)]
<600.000 IU/mL 103 (68.6%) 58 (69.8%) 45 (67.2%) 0.42
P600.000 IU/mL 47 (31.3%) 25 (30.1%) 22 (32.8%)
Fibrosis stage [n (%)]
F1–F2 88 (58.6%) 53 (63.8%) 35 (52.2%) <0.05*
F3–F4 62 (41.4%) 30 (36.2%) 32 (47.8%)
Diabetes mellitus [n (%)]
Absent 125 (83.3%) 75 (90.36%) 52 (77.61%) <0.05*
Present 25 (16.7%) 8 (9.64.3%) 15 (22.39%)
* P< 0.05 significant; SVR, sustained virological response, BMI, body mass index; ALT: alanine transaminase; AST, aspartate transaminase.
Table 3 Genotyping patterns comparison between patients and healthy controls.
HCV patients (n= 150) Healthy control (n= 100) P-value
N % N %
IL-10 (1082 G/A)
 G/G 34 22.7 17 17 0.7
 G/A 63 42.0 57 57
 A/A 53 26.0 26 26
IL-10 (819 C/T)
 C/C 70 46.7 44 44 0.92
 C/T 56 37.3 39 39
 T/T 24 16.0 17 17
IL-10 (592 C/A)
 C/C 60 40 49 49 0.2
 C/A 63 42 40 40
 A/A 27 18 11 11
IFN-c (+874 A/T)
 A/A 29 19.3 17 17 0.89
 A/T 85 56.7 58 58
 T/T 36 24.0 25 25
TNFa (308 G/A)
 G/G 96 64.0 73 73 0.32
 G/A 43 28.7 22 22
 A/A 11 7.3 5 5
TGF-b codon 10 (+869 T/C)
 T/T 42 28 32 32 0.71
 T/C 78 52 47 47
 C/C 30 20 21 21
TGF-b codon 25 (+915 G/C)
 G/G 127 84.7 84 84 0.95
 G/C 22 14.7 15 15
 C/C 1 0.7 1 1
P-value is not significant (>0.05).
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Table 4 Genotyping patterns comparison according to response to therapy.
SVR Relapser Non-responder P-value
All (N= 150) 83 (100%) 18 (100%) 49 (100%)
IL-10 (1082 G/A)
GG (N= 34) 23 (27.7%) 2 (11.1%) 9 (18.3%) 0.004
GA (N= 63) 39 (47.0%) 3 (16.7%) 21(42.9%)
AA (N= 53) 21 (25.3%) 13 (72.2%) 19 (38.8%)
IL-10 (819 C/T)
CC (N= 70) 41 (49.4%) 6 (33.3%) 23 (46.9%) 0.74
CT (N= 56) 28 (33.7%) 9 (50%) 19 (38.8%)
TT (N= 24) 14 (16.9%) 3 (16.7%) 7 (14.3%)
IL-10 (592 C/A)
CC (N= 60) 38 (45.8%) 3 (16.7%) 19 (38.8%) 0.14
CA (N= 63) 30 (36.1%) 12 (66.7%) 21 (42.9%)
AA (N= 27) 15 (18.1%) 3 (16.6%) 9 (18.3%)
IFN-c (+874 A/T)
AA (N= 29) 19 (22.9%) 2 (11.1%) 8 (16.3%) 0.38
AT (N= 85) 48 (57.8%) 9 (50%) 28 (57.2%)
TT (N= 36) 16 (19.3%) 7 (38.9%) 13 (26.5%)
TNF-a (308 G/A)
GG (N= 96) 53 (63.9%) 15 (83.3%) 28 (57.1%) 0.33
GA (N= 43) 24 (28.9%) 2 (11.1%) 17 (34.7%)
AA (N= 11) 6 (7.2%) 1 (5.6%) 4 (8.2%)
TGF-b (+869 T/C)
TT (N= 42) 22 (26.5%) 3 (16.6%) 17 (34.7%) 0.43
TC (N= 78) 45 (54.2%) 9 (50%) 24 (48.9%)
CC (N= 30) 16 (19.3%) 6 (33.4%) 8 (16.4%)
TGF-b (+915 G/C)
GG (n= 127) 68 (81.9%) 14 (77.7%) 45 (91.8%) 0.35
GC (N= 22) 14 (16.9%) 4 (22.3%) 4 (8.2%)
CC (N= 1) 1 (1.2%) 0 (0%) 0 (0%)
Genetic Polymorphisms and HCV Clearance 7It has become clear that bi-allelic polymorphisms at posi-
tions 1082, 819 and 592 have important implications in
differential IL-10 expression in humans [26]. There are conflict-
ing data on the role of the regulatory IL-10 in HCV infection.
The polymorphisms in the IL-10 gene promoter may be a host
factor affecting viral persistence and response to IFN-a
therapy [27].
In this study, no significant difference was observed
between patients and control subjects regarding IL-10 poly-
morphic genetic patterns which reflect that different genetic
patterns of IL-10 do not influence HCV infection susceptibil-
ity. These results are corresponding to previous reports which
found that the distribution of IL-10 promoter gene polymor-
phisms at positions 1082, 819 and 592 was comparable
between HCV patients and healthy controls [28,29].
In contrast, Vidigal et al. [30] reported that IL-10 gene pro-
moter 1082 GG genotype occurred more frequently in HCV
patients than in controls and the GG homozygosity was asso-
ciated with poor response to IFN. However, this study focused
on a limited number of both patients and control subjects.
The present study confirmed that the IL-10 polymorphism
at position (1082) GG genotype is a good predictor of SVR,
independent of other factors, such as age, gender and viral
load. The findings demonstrated in the current study are con-
sistent with previous reports showing that PEG–IFN/RBV
therapy is more effective at blocking the production of HCV
in patients with 1082GG IL-10 promoter genotype and thatPlease cite this article in press as: Obada M et al., Impact of genetic polymorphism
Egyptian patients, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhthe rate of viral decline is increased in patients with the GG
compared to the GA or AA genotypes, which correlates with
higher rates of SVR [29,31,32].
Previously published data found that IL-10 genetic poly-
morphism has been correlated with poor response to interferon
therapy [29,30,33–37]. The reasons for these discrepancies are
not clear. The study populations may differ with regard to fac-
tors that influence SVR: viral load, obesity, fibrosis, ethnicity
and sex. Additional studies are required to define the roles of
these factors in connection with IL10 polymorphisms in
chronic hepatitis C.
At the same time, we did not find any relationship between
IL-10 promoter polymorphism at positions 819 and 592,
and response to IFN therapy. Many authors failed to find
any relationship between the IL-10 promoter polymorphism
at positions 819 and 592 with the response to IFN therapy
[29,30,33–37]. On the contrary, an association between the
819T and 592A SNP with SVR was reported in other stud-
ies in which 819T/T and 592A/A genotypes were signifi-
cantly associated with SVR to IFN-a therapy [38,39].
Our findings could be explained on the basis that genetic
polymorphism in the IL-10 gene promoter leads to alterations
of specific transcription factor recognition sites. This substitu-
tion may affect transcriptional activation, leading to differing
rates of IL-10 mRNA synthesis and cytokine production
[40]. IL-10, produced by monocytes, macrophages and T cells,
inhibits both the activation of CD4 + T-helper cells and thes of four cytokine genes on treatment induced viral clearance in HCV infected
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8 M. Obada et al.function of cytotoxic CD8 + T, NK and antigen-presenting
cells, and also modulates hepatic stellate cell collagen synthe-
sis. IL-10 plays a regulatory role in immune reaction and
suppresses inflammatory responses by inhibiting the produc-
tion of pro-inflammatory cytokines. It may decrease circulat-
ing TFN-a and IL-6 levels, thus, reducing their harmful
effects [32,41–43].
There are conflicting data about the role of IL-10 in HCV-
immune response. Elevated IL-10 production is believed to
mitigate the effects of IFN, which involves direct inhibition
of IFN-activated signal transducer and activator of
transcription-1 (STAT1) in the liver, thus inhibiting the tran-
scription of interferon-stimulated genes, leading to the
decreased expression of certain proteins with known antiviral
activity [44–46].
The present study also analyzed the association between
IFN-c (+874 A/T), TNF-a (308 G/A) and TGF-b (+869
T/C and +915 G/C) gene polymorphism and response to com-
bined therapy in this cohort of CHC patients. No significant
difference was observed between patient and control groups
regarding these SNPs which reflect that these different genetic
patterns do not influence HCV infection susceptibility. They
also have no relation to the response to therapy. These results
were in agreement with previous works conducted by Abbott
et al. [47], Dai et al. [48] and Sarvari et al. [49] who did not
demonstrate any association between the genotype patterns
of INF-c (+874 A/T) with either viral clearance or treatment
response. Romani et al. [22] also did not find any relation
between TGF-b (+869 T/C) gene polymorphism and treat-
ment response. As regards TNF-a, Schiemann et al. [50]
reported that there was no correlation between +308 TNF-a
promoter polymorphisms and the response to combination
therapy of PEG–IFN/RBV in patients with chronic HCV
infection.
In conclusion, we proved that HCV genotype 4 infected
patients with 1082 GG genotype achieved better response
to therapy. Well-adapted therapies should be based on the
baseline characteristics of the patients and should follow a
response-guided approach. According to our data, the pres-
ence of the 1082 GG IL-10 promoter genotype may indicate
a high probability of achieving SVR.
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